Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Immethridine SCHEMBL27875904 | 0.90 | HDAC1 (0.38) | HRH4HRH3CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL649075 | 0.82 | ALDH1A1 (0.46) | HRH4HRH3SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL6973867 | 0.79 | HDAC1 (0.37) | CYP3A4SMN1; SMN2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6973872 | 0.79 | GRIN2B (0.40) | CYP17A1HDAC1HDAC6 | |
| SCHEMBL6972732 | 0.78 | NOTUM (0.39) | ALDH1A1CYP1A2POLBLTA4H | |
| SCHEMBL3149298 | 0.78 | L3MBTL1 (0.49) | HRH3CYP3A4MAPTSMN1; SMN2CYP11B1 | |
| SCHEMBL6971279 | 0.78 | HRH3 (0.38) | HRH3LOXL2 | |
| SCHEMBL11050091 | 0.78 | LPL (0.36) | HRH3MAPTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL11047959 | 0.78 | HSP90AB1 (0.47) | ALDH1A1LTA4H | |
| SCHEMBL8001600 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269123-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-15 | — | — | US | disclosed |
| CN-111670247-B | Method for preparing cancer spheroids and method for selecting colorectal cancer patients | 京诊断株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-20210147812-A1 | Method of Preparing Cancer Spheroid and Method of Selecting Colorectal Cancer Patient | KYO DIAGNOSTICS K.K. (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3722417-A1 | CANCER SPHEROID PRODUCTION METHOD AND METHOD FOR SELECTING COLON CANCER PATIENTS | Kyo Diagnostics K.K. (JP) | 2020-10-14 | — | — | EP | disclosed |
| CN-111670247-A | Method for preparing cancer spheroids and method for selecting colorectal cancer patients | 京诊断株式会社 | 2020-09-15 | — | — | CN | disclosed |
| CN-102481292-A | Novel pharmaceutically acceptable salts of 4- (1H-imidazol-4-ylmethyl) pyridine and their therapeutic applications | BIOPROJET SOC CIV | 2012-05-30 | — | — | CN | disclosed |
| CN-102481292-A | Novel pharmaceutically acceptable salts of 4- (1H-imidazol-4-ylmethyl) pyridine and their therapeutic applications | BIOPROJET SOC CIV | 2012-05-30 | — | — | CN | disclosed |
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2432469-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2263672-A1 | Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses | BIOPROJET (FR) | 2010-12-22 | — | — | EP | disclosed |
| EP-2263672-A1 | Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses | BIOPROJET (FR) | 2010-12-22 | — | — | EP | disclosed |
| EP-2263672-A1 | Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses | BIOPROJET (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010133598-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133598-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | DPP4, PDE8A, PDE8B | HRH4 99/4885HRH3 513/4885CYP3A4 48/4885 |
| US-20240269123-A1 | MUSCLE REGENERATION PROMOTER | MUSK, HRH3, HGF | HRH4 7/4885HRH3 2/4885CYP3A4 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.